Compare Incyte Corporation (INCY) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Uranium Energy Corp — how do they compare? Incyte Corporation trades at $117.9 (market cap $23.11B), while Uranium Energy Corp trades at $9.62 (market cap $4.65B). The key difference: Incyte Corporation is far larger — about 5× Uranium Energy Corp's market cap, and Incyte Corporation is trading nearer its 52-week high, Uranium Energy Corp nearer its low. Which is the better fit depends on your goals.
| INCY | UEC | |
|---|---|---|
Market Cap | $23.11B | $4.65B |
Sector | Health | Energy |
52-Week High | $118.52 | $20.14 |
52-Week Low | $67.38 | $8.00 |
Enterprise Value | $19.13B | $4.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
UEC trades at $9.40, up 1.29% today, but faces bearish technical signals with 18 sell indicators against 2 buys. The company reported a net loss of $87.66 million in 2025 on $66.84 million revenue, with a negative net margin of -513.24% in 2026. Recent news highlights operational challenges, including zero sales in Q3 2026 and wider losses, though strategic assets and $794 million liquidity offer some stability.
Despite analyst consensus favoring buys (87.5%), high execution risks and persistent losses temper near-term optimism. Investment appeal hinges on successful production ramp-up and uranium price recovery, but volatility and cost pressures present significant downside risks for stockholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
